Cancer is one of the leading causes of death worldwide, and distant metastases cause more than 90% of cancer deaths. Due to the limited resolution of imaging technologies such as bioluminescence and MRI, scientists have not been able to comprehensively detect metastatic cells throughout the body, which has greatly… Continue Reading Cell releases blockbuster black technology: fully revealing cancer metastasis
Figure ①: Antitumor biology of γδ T cells Figure 1 illustrates the antitumor function of γδ T cells and its regulatory mechanism. γδ T cells directly recognize tumor cells through T cell receptors (TCR) and natural killer cell receptors (NKRs), and regulate tumor cell killing through a variety of… Continue Reading Cancer immunotherapy 12 pictures
Immunotherapy is considered to be the fourth pillar of cancer treatment (in parallel with surgery, radiotherapy, and chemotherapy), by enhancing the ability of the immune system to target and kill tumor cells, including: 1) Blocking antibodies to the inhibitory immune checkpoint pathway 2) Cell therapy based on dendritic cells… Continue Reading Nature: The next step in cancer immunotherapy is joint therapy. Eradication of cancer is not the ultimate goal.
Metabolism involves a series of biochemical reactions that convert nutrients into metabolites that play an important role in maintaining cellular homeostasis and in response to intracellular and extracellular stimuli. Metabolic changes are one of the important features of tumors. In order to maintain sustained proliferation, tumor cells must adjust… Continue Reading The next wave of cancer immunotherapy – regulating metabolism
Drug: metformin Magazine: Nature and its publications Highlights: 1) Metformin + heme inhibits tumor growth in triple negative breast cancer 2) Metformin + BCL-2 inhibitor + PD-1 antibody can significantly prolong the survival of breast cancer mice Metformin was discovered in 1922 and began clinical application in 1957.… Continue Reading Metformin combined treatment of breast cancer is expected
Drug: NKG2A antibody Magazine: Cell & Nature Highlights: Cancer immunotherapy has a new target – NKG2A, I / II clinical trial data “giving expectations”, but the future is still unclear In recent years, cancer immunotherapy has achieved unprecedented success, but only a few patients have shown lasting efficacy. Improving… Continue Reading A new target for cancer immunotherapy – NKG2A, the future is unknown
On February 14, Merck announced the interim results of the Ib/II umbrella study KEYNOTE-365 at the American Society of Clinical Oncology Urology Tumor Symposium (ASCO GU). KEYNOTE-365 is a developmental, multicenter, multi-cohort, non-randomized study evaluating the efficacy of a fixed dose of Keytruda (200 mg once every 3 weeks)… Continue Reading Merck initiates the largest clinical trial of PD-1/PD-L1 prostate cancer
Drug: SA-4-1BBL Magazine: Cancer Research Highlights: A new immunotherapy that promises to prevent multiple cancers T cells play an important role in the defense against cancer, and their activation is regulated by ligand-receptor interactions on macrophages in T cells, dendritic cells, tumor cells, and tumor microenvironments. . These… Continue Reading US scientists confirm for the first time: immunotherapy is expected to prevent multiple cancers
I Mysterious disappearing tumor In the oncology department for a long time, there is always a chance to meet miracles. About ten years ago, Archie Tse also worked at the Sloan-Kettering Cancer Center. At that time, he took over a patient with advanced pancreatic cancer. The prognosis of most patients… Continue Reading STING Hunter: Can a new generation of therapy sweep the field of tumor immunity?
At present, there are as many as 100 PD-1/PD-L1 projects in the world (China accounts for more than 1/4). This can not help but cause everyone’s doubts: Is it possible for the pharmaceutical industry to develop R&D projects in a certain target/disease area? Have you invested too much money? Prior… Continue Reading Is the pharmaceutical industry excessively investing in the research and development of cancer?